{"product_id":"recombinant-sudan-ebolavirus-envelope-glycoprotein-gp-partial-bhp10509083","title":"Recombinant Sudan ebolavirus Envelope glycoprotein (GP), partial","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eRecombinant Sudan ebolavirus Envelope glycoprotein (GP), partial is a recombinant protein reagent derived from Sudan ebolavirus (strain Uganda-00) (SEBOV) (Sudan Ebola virus) and produced in E.coli. It is commonly used to support Others research by enabling binding assays, assay development and protein–protein interaction studies in controlled in vitro settings.\u003c\/p\u003e \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e \u003cli\u003e\n\u003cstrong\u003eExpressed region:\u003c\/strong\u003e 502-637aa. Region selection can focus on functional domains, improve solubility, or isolate interaction surfaces for targeted studies.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eExpression system:\u003c\/strong\u003e E.coli. Expression host can influence folding and the presence\/absence of post-translational modifications.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eTag \/ fusion:\u003c\/strong\u003e N-terminal 6xHis-KSI-tagged. Tags can support purification and detection; evaluate potential tag effects when studying sensitive interactions.\u003c\/li\u003e \u003cli\u003e\n\u003cstrong\u003eMolecular weight (reported):\u003c\/strong\u003e 30.8 kDa. Apparent size may vary with tags, processing, and gel conditions.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eWhen comparing results across batches or platforms, interpret signals in the context of construct design (region, tags) and expression host, especially for modification-dependent interactions.\u003c\/p\u003e \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003eThe gene commonly associated with this target is \u003cstrong\u003eGP\u003c\/strong\u003e. GP refers to a protein target that is studied across multiple biological contexts; annotations and nomenclature can vary by species and isoform. This product corresponds to the Sudan ebolavirus (strain Uganda-00) (SEBOV) (Sudan Ebola virus) sequence context, which can be important when comparing homologs or orthologs across model systems. For curated functional annotations, domains, and sequence features, consult primary databases (e.g., UniProt\/NCBI) and the recent literature for the specific organism and isoform.\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e \u003cli\u003eUsing recombinant proteins to enable quantitative binding measurements and reagent benchmarking.\u003c\/li\u003e \u003cli\u003eStudying domain- and isoform-specific effects in pathway models and interaction networks.\u003c\/li\u003e \u003cli\u003eDeveloping robust, reproducible assays that connect molecular readouts to cellular phenotypes.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003e\u003cstrong\u003eRelevance:\u003c\/strong\u003e [Envelope glycoprotein]: Trimeric GP1,2 complexes form the virion surface spikes and mediate the viral entry processes, with GP1 acting as the receptor-binding subunit and GP2 as the membrane fusion subunit. At later times of infection, downregulates the expression of various host cell surface molecules that are essential for immune surveillance and cell adhesion. Down-modulates several integrins including ITGA1, ITGA2, ITGA3, ITGA4, ITGA5, ITGA6, ITGAV and ITGB1. This decrease in cell adhesion molecules may lead to cell detachment, contributing to the disruption of blood vessel integrity and hemorrhages developed during infection (cytotoxicity). Interacts with host TLR4 and thereby stimulates the differentiation and activation of monocytes leading to bystander death of T-lymphocytes. Downregulates as well the function of host natural killer cells. Counteracts the antiviral effect of host BST2\/tetherin that restricts release of progeny virions from infected cells. However, cooperates with VP40 and host BST2 to activate canonical NF-kappa-B pathway in a manner dependent on neddylation.; [Shed GP]: Functions as a decoy for anti-GP1,2 antibodies thereby contributing to viral immune evasion. Interacts and activates host macrophages and dendritic cells inducing up-regulation of cytokine transcription. This effect is mediated throught activation of host TLR4.; [GP1]: Responsible for binding to the receptor(s) on target cells. Interacts with CD209\/DC-SIGN and CLEC4M\/DC-SIGNR which act as cofactors for virus entry into dendritic cells (DCs) and endothelial cells (By similarity). Binding to the macrophage specific lectin CLEC10A also seems to enhance virus infectivity (By similarity). Interaction with FOLR1\/folate receptor alpha may be a cofactor for virus entry in some cell types, although results are contradictory (By similarity). Members of the Tyro3 receptor tyrosine kinase family also seem to be cell entry factors in filovirus infection (By similarity). Once attached, the virions are internalized through clathrin-dependent endocytosis and\/or macropinocytosis. After internalization of the virus into the endosomes of the host cell, proteolysis of GP1 by two cysteine proteases, CTSB\/cathepsin B and CTSL\/cathepsin L removes the glycan cap and allows GP1 binding to the host entry receptor NPC1. NPC1-binding, Ca(2+) and acidic pH induce a conformational change of GP2, which unmasks its fusion peptide and permit membranes fusion (By similarity).; [GP2]: Acts as a class I viral fusion protein. Under the current model, the protein has at least 3 conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and target cell membrane fusion, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes. Responsible for penetration of the virus into the cell cytoplasm by mediating the fusion of the membrane of the endocytosed virus particle with the endosomal membrane. Low pH in endosomes induces an irreversible conformational change in GP2, releasing the fusion hydrophobic peptide.\u003c\/p\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e \u003cli\u003eAssay and standard development for immunoassays or binding-based detection methods.\u003c\/li\u003e \u003cli\u003eProtein–protein interaction studies (e.g., receptor–ligand or complex assembly) using purified components.\u003c\/li\u003e \u003cli\u003eStructure–function analysis, including domain mapping or evaluation of sequence variants.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eIn quantitative assay development, changes in binding or activity readouts are typically interpreted relative to appropriate negative\/positive controls and, where possible, orthogonal assay formats that support the same conclusion.\u003c\/p\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e \u003cli\u003eRecombinant constructs may represent a defined region (domain) rather than the full-length protein; interpret results in the context of the expressed region.\u003c\/li\u003e \u003cli\u003eTag or fusion elements can aid purification and detection but may influence binding surfaces or oligomerization; consider tag controls when relevant.\u003c\/li\u003e \u003cli\u003eSpecies and isoform differences can affect interaction partners and post-translational modifications; align experimental controls to the intended biological context.\u003c\/li\u003e \u003cli\u003eE. coli expression can limit eukaryotic post-translational modifications; for modification-dependent biology, interpret results accordingly.\u003c\/li\u003e \u003c\/ul\u003e \u003c!-- Sources (internal): - UniProtKB entry for Q7T9D9 — UniProt — https:\/\/www.uniprot.org\/uniprotkb\/Q7T9D9\/entry - NCBI Gene search (GP) — NCBI — https:\/\/www.ncbi.nlm.nih.gov\/gene\/?term=GP - PubMed search (GP) — NCBI — https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=GP - RCSB PDB search (GP) — RCSB PDB — https:\/\/www.rcsb.org\/search?query=GP - Reactome Pathway Browser — Reactome — https:\/\/reactome.org\/ --\u003e","brand":"CUSABIO TECHNOLOGY LLC","offers":[{"title":"1 mg","offer_id":53065276424557,"sku":"CSB-EP742487SRE-1MG","price":2466.0,"currency_code":"USD","in_stock":true},{"title":"100 ug","offer_id":53065400582509,"sku":"CSB-EP742487SRE-100UG","price":729.0,"currency_code":"USD","in_stock":true},{"title":"20 ug","offer_id":53065400615277,"sku":"CSB-EP742487SRE-20UG","price":388.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/CSB-EP742487SRE-SDS.jpg?v=1772476417","url":"https:\/\/www.ebiohippo.com\/products\/recombinant-sudan-ebolavirus-envelope-glycoprotein-gp-partial-bhp10509083","provider":"BioHippo","version":"1.0","type":"link"}